Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer - Fig 2

<p>Kaplan–Meier overall survival curves after the diagnosis of NSCLC in all patients with or without pneumonitis during systemic anti-cancer therapy (pneumonitis) (Fig 2A) and those who did not have pre-existing ILD with or without pneumonitis (Fig 2B), and survival time after the onset of pneumonitis in survivors of pneumonitis (Fig 2C).</p

Analyses of survival time after pneumonitis during systemic anti-cancer therapy (N = 28^*)

<p>Analyses of survival time after pneumonitis during systemic anti-cancer therapy (N = 28^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0168465#t005fn002" target="_blank">*</a>})</p

Analyses of overall survival time in all patients (N = 770)

<p>Analyses of overall survival time in all patients (N = 770)</p

Characteristics and outcomes of patients with pneumonitis during systemic anti-cancer therapy (N = 44)

<p>Characteristics and outcomes of patients with pneumonitis during systemic anti-cancer therapy (N = 44)</p

Characteristics of and comparison between patients with and without pneumonitis during systemic anti-cancer therapy

<p>Characteristics of and comparison between patients with and without pneumonitis during systemic anti-cancer therapy</p

Factors associated with pneumonitis during systemic anti-cancer therapy (N = 770)

<p>Factors associated with pneumonitis during systemic anti-cancer therapy (N = 770)</p

Additional file 2: Figure S1. of The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma

Scatter-plot of serum CA 19-9 and CYFRA 21-1 levels. (JPG 394 kb